✦ LIBER ✦

Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine

✍ Scribed by Dermot R Fitzgibbon; L.Brian Ready

Book ID: 117479832
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 59 KB
Volume: 73
Category: Article
ISSN: 0304-3959
DOI: 10.1016/s0304-3959(97)00118-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient-Controlled Analgesia With Intrav

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine

✍ Rainer Sabatowski; Stefan M Kasper; Lukas Radbruch 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Pain and Practicalities: The Experience

Pain and Practicalities: The Experience of Transitioning a Young Cancer Patient from High-Dose Hydromorphone Therapy to Intravenous Methadone in an Academic Medical Center (736)

✍ Virginia LeBaron; Jacqueline Brody; Ellyn Lee; Linda Snyder 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Bowel rest, intravenous hydration, and c

Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma

✍ Nicholas J. Petrelli; Miguel Rodriguez-Bigas; Youcef Rustum; Lemuel Herrera; Pat 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB 👁 2 views

A Phase I dose escalation trial of conti

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

✍ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou